Skip to main content
Top
Published in: Pathology & Oncology Research 3/2015

01-07-2015 | Review

The Role of the Mediators of Inflammation in Cancer Development

Authors: José Veríssimo Fernandes, Ricardo Ney Oliveira Cobucci, Carlos André Nunes Jatobá, Thales Allyrio Araújo de Medeiros Fernandes, Judson Welber Veríssimo de Azevedo, Josélio Maria Galvão de Araújo

Published in: Pathology & Oncology Research | Issue 3/2015

Login to get access

Abstract

Epigenetic disorders such as point mutations in cellular tumor suppressor genes, DNA methylation and post-translational modifications are needed to transformation of normal cells into cancer cells. These events result in alterations in critical pathways responsible for maintaining the normal cellular homeostasis, triggering to an inflammatory response which can lead the development of cancer. The inflammatory response is a universal defense mechanism activated in response to an injury tissue, of any nature, that involves both innate and adaptive immune responses, through the collective action of a variety of soluble mediators. Many inflammatory signaling pathways are activated in several types of cancer, linking chronic inflammation to tumorigenesis process. Thus, Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, growth, invasion, and metastasis, affecting also the immune surveillance. Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells, and some of the molecular events that mediate this dialog have been revealed. A range of inflammation mediators, including cytokines, chemokines, free radicals, prostaglandins, growth and transcription factors, microRNAs, and enzymes as, cyclooxygenase and matrix metalloproteinase, collectively acts to create a favorable microenvironment for the development of tumors. In this review are presented the main mediators of the inflammatory response and discussed the likely mechanisms through which, they interact with each other to create a condition favorable to development of cancer.
Literature
1.
go back to reference Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229–265CrossRefPubMed Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229–265CrossRefPubMed
2.
go back to reference Ashley NT, Weil ZM, Nelson RJ (2012) Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst 43:385–406CrossRef Ashley NT, Weil ZM, Nelson RJ (2012) Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst 43:385–406CrossRef
3.
go back to reference Bermejo-Martin JF, Martín-Loeches I, Bosinger S (2014) Inflammation and infection in critical care medicine. Mediat Inflamm 2014:456256. doi:10.1155/2014/456256 Bermejo-Martin JF, Martín-Loeches I, Bosinger S (2014) Inflammation and infection in critical care medicine. Mediat Inflamm 2014:456256. doi:10.​1155/​2014/​456256
5.
go back to reference Campbell LM, Maxwell PJ, Waugh DJ (2013) Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals 6(8):929–959CrossRefPubMedCentralPubMed Campbell LM, Maxwell PJ, Waugh DJ (2013) Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals 6(8):929–959CrossRefPubMedCentralPubMed
6.
go back to reference Kaushal N, Kudva AK (2013) Oxidative stress and inflammation: the lesser of two evils in carcinogenesis. PostDoc J 1(2):89–101 Kaushal N, Kudva AK (2013) Oxidative stress and inflammation: the lesser of two evils in carcinogenesis. PostDoc J 1(2):89–101
7.
go back to reference Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4(8):617–629CrossRefPubMed Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4(8):617–629CrossRefPubMed
8.
go back to reference Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121(11):2373–2380CrossRefPubMed Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121(11):2373–2380CrossRefPubMed
9.
go back to reference Adefuye A, Sales K (2012) Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) 2012:548150 Adefuye A, Sales K (2012) Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) 2012:548150
10.
go back to reference Allavena P, Germano G, Marchesi F, Mantovani A (2011) Chemokines in cancer related inflammation. Exp Cell Res 317(5):664–673CrossRefPubMed Allavena P, Germano G, Marchesi F, Mantovani A (2011) Chemokines in cancer related inflammation. Exp Cell Res 317(5):664–673CrossRefPubMed
13.
go back to reference Liang Y, Zhou Y, Shen P (2004) NF-kappaB and its regulation on the immune system. Cell Mol Immunol 1(5):343–350PubMed Liang Y, Zhou Y, Shen P (2004) NF-kappaB and its regulation on the immune system. Cell Mol Immunol 1(5):343–350PubMed
14.
go back to reference Wu LJ, Li HX, Luo XT et al (2014) STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer. Int J Clin Exp Pathol 7(3):1140–1146PubMedCentralPubMed Wu LJ, Li HX, Luo XT et al (2014) STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer. Int J Clin Exp Pathol 7(3):1140–1146PubMedCentralPubMed
15.
go back to reference Fan Y, Mao R, Yang J (2013) NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4(3):176–185CrossRefPubMed Fan Y, Mao R, Yang J (2013) NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4(3):176–185CrossRefPubMed
17.
go back to reference Löffek S, Schilling O, Franzke CW (2011) Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 38:191–208CrossRefPubMed Löffek S, Schilling O, Franzke CW (2011) Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 38:191–208CrossRefPubMed
18.
go back to reference Walter L, Harper C, Gar P (2013) Role of matrix metalloproteinases in inflammation/colitis-associated colon cancer. Immuno-Gastroenterology 2(1):22–28CrossRef Walter L, Harper C, Gar P (2013) Role of matrix metalloproteinases in inflammation/colitis-associated colon cancer. Immuno-Gastroenterology 2(1):22–28CrossRef
19.
go back to reference Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L (2013) Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediat Inflamm 2013:928315. doi:10.1155/2013/928315 Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L (2013) Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediat Inflamm 2013:928315. doi:10.​1155/​2013/​928315
20.
go back to reference Butler GS (2000) Overall CM (2013) Matrix metalloproteinase processing of signaling molecules to regulate inflammation. Periodontol 63(1):123–148CrossRef Butler GS (2000) Overall CM (2013) Matrix metalloproteinase processing of signaling molecules to regulate inflammation. Periodontol 63(1):123–148CrossRef
23.
go back to reference Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215(1):1–20CrossRefPubMed Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215(1):1–20CrossRefPubMed
24.
go back to reference Cathcart MC, O’Byrne KJ, Reynolds JV, O’Sullivan J, Pidgeon GP (2012) COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta 1825(1):49–63PubMed Cathcart MC, O’Byrne KJ, Reynolds JV, O’Sullivan J, Pidgeon GP (2012) COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta 1825(1):49–63PubMed
27.
go back to reference Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA (2012) Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 188(5):2445–2454CrossRefPubMed Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA (2012) Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 188(5):2445–2454CrossRefPubMed
28.
go back to reference Sales KJ, Katz AA, Howard B et al (2002) Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62:424–432PubMedCentralPubMed Sales KJ, Katz AA, Howard B et al (2002) Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62:424–432PubMedCentralPubMed
29.
go back to reference zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384(2):260–265CrossRefPubMed zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384(2):260–265CrossRefPubMed
30.
go back to reference Ahmad J, Hasnain SE, Siddiqui MA, Ahamed M, Musarrat J, Al-Khedhairy AA (2013) MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J Med Res 137(4):680–694PubMedCentralPubMed Ahmad J, Hasnain SE, Siddiqui MA, Ahamed M, Musarrat J, Al-Khedhairy AA (2013) MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J Med Res 137(4):680–694PubMedCentralPubMed
32.
go back to reference Ostermann E, Laventie JR, Pfeffer S, Bahram S, Sprauel PS, Georgel P (2013) MicroRNAs: Fine-turners of type-I interferon-dependent inflammatory responses. Curr Trends Immunol 14:35–44 Ostermann E, Laventie JR, Pfeffer S, Bahram S, Sprauel PS, Georgel P (2013) MicroRNAs: Fine-turners of type-I interferon-dependent inflammatory responses. Curr Trends Immunol 14:35–44
33.
go back to reference Tili E, Michaille JJ, Croce CM (2013) MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 253(1):167–184CrossRefPubMed Tili E, Michaille JJ, Croce CM (2013) MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 253(1):167–184CrossRefPubMed
36.
go back to reference O’Connell RM, Rao DS, Baltimore D (2012) MicroRNA regulation of inflammatory responses. Annu Rev Immunol 30:295–312CrossRefPubMed O’Connell RM, Rao DS, Baltimore D (2012) MicroRNA regulation of inflammatory responses. Annu Rev Immunol 30:295–312CrossRefPubMed
37.
go back to reference Chiba T, Marusawa H, Ushijima T (2012) Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143(3):550–563CrossRefPubMed Chiba T, Marusawa H, Ushijima T (2012) Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143(3):550–563CrossRefPubMed
39.
go back to reference Tang T, Wong HK, Gu W et al (2013) MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol 129(1):199–208CrossRefPubMed Tang T, Wong HK, Gu W et al (2013) MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol 129(1):199–208CrossRefPubMed
40.
go back to reference Zhou Q, Haupt S, Kreuzer JT et al (2014) Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204377 Zhou Q, Haupt S, Kreuzer JT et al (2014) Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2013-204377
42.
go back to reference Josse C, Bouznad N, Geurts P et al (2014) Identification of a microRNA landscape targeting the PI3K/Akt signaling pathway in inflammation-induced colorectal carcinogenesis. Am J Physiol Gastrointest Liver Physiol 306(3):G229–G243CrossRefPubMed Josse C, Bouznad N, Geurts P et al (2014) Identification of a microRNA landscape targeting the PI3K/Akt signaling pathway in inflammation-induced colorectal carcinogenesis. Am J Physiol Gastrointest Liver Physiol 306(3):G229–G243CrossRefPubMed
43.
go back to reference Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J (2013) Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia 15(4):409–420CrossRefPubMedCentralPubMed Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J (2013) Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia 15(4):409–420CrossRefPubMedCentralPubMed
44.
go back to reference Lou JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell 6(3):297–305CrossRef Lou JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell 6(3):297–305CrossRef
45.
go back to reference Waters JP, Pober JS, Bradley JR (2013) Tumour necrosis factor and cancer. J Pathol 230(3):241–248CrossRefPubMed Waters JP, Pober JS, Bradley JR (2013) Tumour necrosis factor and cancer. J Pathol 230(3):241–248CrossRefPubMed
46.
48.
go back to reference Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23(9):2078–2093CrossRefPubMed Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23(9):2078–2093CrossRefPubMed
50.
go back to reference Visperas A, Do JS, Bulek K, Li X, Min B (2014) IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol 7(3):625–633CrossRefPubMedCentralPubMed Visperas A, Do JS, Bulek K, Li X, Min B (2014) IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol 7(3):625–633CrossRefPubMedCentralPubMed
51.
go back to reference Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904–910CrossRefPubMed Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904–910CrossRefPubMed
52.
go back to reference Vicari AP, Trinchieri G (2004) Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev 202:223–236CrossRefPubMed Vicari AP, Trinchieri G (2004) Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev 202:223–236CrossRefPubMed
53.
go back to reference Mocelin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78:1043–1051CrossRef Mocelin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78:1043–1051CrossRef
54.
go back to reference Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ (2004) Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 135(1):64–73CrossRefPubMedCentralPubMed Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ (2004) Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 135(1):64–73CrossRefPubMedCentralPubMed
55.
go back to reference Pattison MJ, MacKenzie KF, Arthur JS (2012) Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol 189(6):2784–2792CrossRefPubMedCentralPubMed Pattison MJ, MacKenzie KF, Arthur JS (2012) Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol 189(6):2784–2792CrossRefPubMedCentralPubMed
56.
go back to reference Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51(2–3):170–82CrossRefPubMed Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51(2–3):170–82CrossRefPubMed
57.
go back to reference Cope A, Le Friec G, Cardone J, Kemper C (2011) The Th1 life cycle: molecular control of IFN-γ to IL-10 switching. Trends Immunol 32(6):278–286CrossRefPubMed Cope A, Le Friec G, Cardone J, Kemper C (2011) The Th1 life cycle: molecular control of IFN-γ to IL-10 switching. Trends Immunol 32(6):278–286CrossRefPubMed
58.
go back to reference Stewart CA, Metheny H, Iida N et al (2013) Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest 123(11):4859–4874CrossRefPubMedCentralPubMed Stewart CA, Metheny H, Iida N et al (2013) Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest 123(11):4859–4874CrossRefPubMedCentralPubMed
59.
go back to reference Shigehara K, Shijubo N, Ohmichi M et al (2001) IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J Immunol 166(1):642–649CrossRefPubMed Shigehara K, Shijubo N, Ohmichi M et al (2001) IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J Immunol 166(1):642–649CrossRefPubMed
60.
go back to reference Wong JL, Berk E, Edwards RP, Kalinski P (2013) IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 73(15):4653–4662CrossRefPubMedCentralPubMed Wong JL, Berk E, Edwards RP, Kalinski P (2013) IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 73(15):4653–4662CrossRefPubMedCentralPubMed
61.
go back to reference Srivastava S, Salim N, Robertson MJ (2010) Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem 17(29):3353–3357CrossRefPubMed Srivastava S, Salim N, Robertson MJ (2010) Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem 17(29):3353–3357CrossRefPubMed
62.
go back to reference Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA, Ciliberto G, Arra C (2013) Interleukin 18: friend or foe in cancer. Biochim Biophys Acta 1836:296–303PubMed Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA, Ciliberto G, Arra C (2013) Interleukin 18: friend or foe in cancer. Biochim Biophys Acta 1836:296–303PubMed
63.
go back to reference Miossec P (2009) IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 11(5):625–630CrossRefPubMed Miossec P (2009) IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 11(5):625–630CrossRefPubMed
64.
go back to reference Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R, Zhu B (2013) Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene. doi:10.1038/onc.2013.537 Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R, Zhu B (2013) Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene. doi:10.​1038/​onc.​2013.​537
65.
go back to reference Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH (2013) Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology 63(2):225–233CrossRefPubMed Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH (2013) Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology 63(2):225–233CrossRefPubMed
67.
go back to reference Ngiow SF, Teng MW, Smyth MJ (2013) Balance of interleukin-12 and −23 in cancer. Trends Immunol 34(11):548–555CrossRefPubMed Ngiow SF, Teng MW, Smyth MJ (2013) Balance of interleukin-12 and −23 in cancer. Trends Immunol 34(11):548–555CrossRefPubMed
Metadata
Title
The Role of the Mediators of Inflammation in Cancer Development
Authors
José Veríssimo Fernandes
Ricardo Ney Oliveira Cobucci
Carlos André Nunes Jatobá
Thales Allyrio Araújo de Medeiros Fernandes
Judson Welber Veríssimo de Azevedo
Josélio Maria Galvão de Araújo
Publication date
01-07-2015
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-015-9913-z

Other articles of this Issue 3/2015

Pathology & Oncology Research 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine